Rotman Research Institute, Baycrest, Toronto, ON, Canada.
Neuropsychology and Cognitive Health, Baycrest, Toronto, ON, Canada.
Neuropsychol Rev. 2020 Mar;30(1):97-125. doi: 10.1007/s11065-020-09428-6. Epub 2020 Mar 12.
Amnestic mild cognitive impairment (aMCI) is a prodromal stage of Alzheimer's disease that is characterized by impairments in episodic memory. Recent evidence has shown that inhibitory control is also impaired in aMCI. The aim of the present meta-analysis was to quantify inhibitory control ability in individuals with aMCI by examining performance across a range of well-defined inhibition paradigms that tapped into one of three inhibitory control subtypes (i) interference control (e.g., Stroop task), (ii) response inhibition (e.g., Go/Nogo task), or (iii) inhibition of cognitive sets (Wisconsin Card Sort Task). Reference databases (PsychINFO, PubMed, and Web of Science) were searched for studies comparing individuals with aMCI to healthy controls on behavioural measures of inhibition. Across 70 effect sizes involving 2184 adults with aMCI and 3049 controls, overall inhibition deficits of moderate magnitude (g = -0.73) were found among individuals with aMCI. Inhibition deficits were moderate in size regardless of inhibitory control subtype: interference control (g = -0.74), response inhibition (g = -0.71), inhibition of cognitive sets (g = -0.76). Subgroup analyses revealed that Stroop outcome measure (reaction time vs. accuracy) and recruitment source (clinical vs. community) moderated interference control deficits. Together these findings support a generalized inhibition deficit in aMCI, and suggest that inhibition tasks should be included routinely in neuropsychological test batteries to provide a more comprehensive overview of executive dysfunction in aMCI.
遗忘型轻度认知障碍 (aMCI) 是阿尔茨海默病的前驱阶段,其特征是情节记忆受损。最近的证据表明,aMCI 患者的抑制控制也受损。本荟萃分析的目的是通过检查一系列明确的抑制范式中的表现来量化 aMCI 个体的抑制控制能力,这些范式涉及三种抑制控制亚型中的一种:(i) 干扰控制(例如,Stroop 任务),(ii) 反应抑制(例如,Go/Nogo 任务),或 (iii) 认知集抑制(威斯康星卡片分类任务)。参考数据库(PsychINFO、PubMed 和 Web of Science)被搜索以比较 aMCI 个体与健康对照组在抑制行为测量上的差异。在涉及 2184 名 aMCI 成年人和 3049 名对照者的 70 个效应量中,发现 aMCI 个体存在中等程度的整体抑制缺陷(g = -0.73)。无论抑制控制亚型如何,抑制缺陷的大小都适中:干扰控制(g = -0.74)、反应抑制(g = -0.71)、认知集抑制(g = -0.76)。亚组分析表明,Stroop 结果测量(反应时间与准确性)和招募来源(临床与社区)调节了干扰控制缺陷。这些发现共同支持 aMCI 中的一般性抑制缺陷,并表明抑制任务应常规纳入神经心理测试组合中,以更全面地了解 aMCI 中的执行功能障碍。